{
    "nct_id": "NCT06045507",
    "official_title": "A Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral MK-8527 Once Monthly in Participants at Low-Risk for HIV-1 Infection",
    "inclusion_criteria": "* Is confirmed HIV-uninfected based on negative HIV-1/HIV-2 test result before randomization\n* Has low-risk of HIV infection\n* Females: is not pregnant or breastfeeding and is either not a participant of childbearing potential (POCBP) OR is a POCBP and uses an acceptable contraception or is abstinent from penile-vaginal intercourse\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 65 Years",
    "exclusion_criteria": "* Has hypersensitivity or other contraindication to any of the components of the study interventions as determined by the investigator\n* Has an active diagnosis of hepatitis due to any cause, including active hepatitis B (HBV) infection (defined as HBsAg-positive) or hepatitis C virus (HCV) infection (defined as detectable HCV ribonucleic acid [RNA])\n* Prior use of MK-8527 or islatravir (MK-8591)",
    "miscellaneous_criteria": ""
}